Predictive signatures for chemotherapy sensitivity in breast cancer: Are they ready for use in the clinic?
Predictive signatures for chemotherapy sensitivity in breast cancer: Are they ready for use in the clinic?
复制标题
DOI：
10.1016/j.ejca.2009.04.036
复制
发表时间：
2009-07-01
影响因子：
8.4
通讯作者：
Cameron, David
中科院分区：
文献类型：
--
作者：
Bonnefoi, Herve;Underhill, Craig;Cameron, David
预测肿瘤对化疗敏感性的标志物必须解决两个问题：（a）哪些肿瘤更可能对化疗反应？和（B）对于特定肿瘤或肿瘤组，什么是最佳化疗方案？为了回答这些问题，将需要一般的化学敏感性和药物特异性化学敏感性的标志物，分别超出这些基本问题在于一个重要的实际问题：在目前的文献中的预测标志物准备常规临床使用？本文的重点是解决这一实际问题。我们将首先回顾回顾性试验，报告有前途的化疗签名，提出了一个全面的方式，为非生物信息学家的不同方法使用到目前为止。此外，我们将总结前瞻性试验（正在进行或正在开发中），旨在测试目前认为预测化疗敏感性的多基因分类器。最后，我们将讨论为什么微阵列研究迄今未能确定新的目标，以及我们如何能够通过大规模的肿瘤基因分型来改善这些结果。(C)2009爱思唯尔有限公司保留所有权利。
Markers that predict the sensitivity of tumours to chemotherapy must address two questions: (a) which tumours are more likely to respond to chemotherapy? and (b) what is the optimal chemotherapy regimen for a specific tumour or group of tumours? To answer these questions will require markers of general chemosensitivity and drug-specific chemosensitivity, respectively Beyond these fundamental questions lies an important practical question: are the predictive markers in the current literature ready for routine clinical use? The focus of this paper is to address this practical question. We will first review retrospective trials that have reported promising chemotherapy signatures, presenting in a comprehensive manner for the non bio-informatician the different methods used so far. In addition, we will summarise prospective trials (either ongoing or under development) designed to test the multigene classifiers currently thought to predict chemosensitivity. Finally, we will discuss why microarray studies have so far failed to identify new targets, and how we might be able to improve on these results through large-scale genotyping of tumours. (C) 2009 Elsevier Ltd. All rights reserved.